What are the contraindications for giritinib/segatan?

Gilitinib/Segatan as an oral small molecule inhibitor targetingFLT3 mutations, provides a new option in the treatment of acute myeloid leukemia (AML), but not all patients are suitable for use. First of all, the clear contraindications are patients who are allergic to giritinib or any of its excipients. There have been reports in clinical trials suggesting allergic reactions, including rash, respiratory symptoms and even severe hypersensitivity reactions. Therefore, it is necessary to understand the patient's past drug allergy history in detail before taking medication.

Secondly, giritinib mainly relies on liver enzymes in the metabolism process, and some patients may be at risk of drug interactions, especially those who are combined with strongCYP3A4 inhibitors or inducers, which may result in excessive or insufficient drug concentration, thus affecting efficacy and safety. Such patients need to adjust the dosage or avoid simultaneous use under the guidance of a professional physician. Patients with severely impaired liver function also need to be carefully evaluated because the drug's ability to clear the drug in the body is reduced, which may increase the incidence of adverse reactions.

In addition, giritinib treatment may cause electrocardiogramQT interval prolongation, electrolyte imbalance and liver enzyme elevation. Therefore, patients with previous severe heart disease, uncorrected hypokalemia or hypomagnesemia should be used under strict monitoring, and alternatives should be considered if necessary. In pregnant and lactating women, the use of gilitinib is expressly prohibited due to a lack of adequate safety data to avoid potential risks to the fetus or newborn.

Overall, the safety of giritinib needs to be evaluated before decision-making. Risks can be minimized through standardized genetic testing, allergy history inquiries before medication, liver and kidney function assessment, and cardiac monitoring. In the context of precision medicine, reasonably identifying contraindication groups and strengthening monitoring will not only help improve drug efficacy, but also bring longer-term survival benefits to patients.

Reference materials:https://www.xospata.com/